|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 480.22 DKK | -0.47% |
|
-7.41% | -22.98% |
| Jun. 18 | US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list | RE |
| Jun. 18 | US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list | RE |
Main competitors
| Consensus (Composite) | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Ecart obj. / dr | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| DKK 662.91 | +37.39% | 22 | |||||||
| $951.98 | +21.27% | 27 | |||||||
| $169.18 | +12.24% | 23 | |||||||
| $208.86 | +12.6% | 27 | |||||||
| CHF 302.63 | +16.8% | 20 | |||||||
| - | CHF 118.73 | +2.14% | 19 | ||||||
| GBX 179.12 | +26.04% | 20 | |||||||
| $101.79 | +28.37% | 24 | |||||||
| $314.7 | +8.65% | 28 | |||||||
| $29.24 | +22.44% | 23 | |||||||
| $116.77 | +8.12% | 26 | |||||||
| €114.73 | +38.55% | 23 | |||||||
| $499.87 | +11.48% | 28 | |||||||
| $57.1 | +21.9% | 22 | |||||||
| ¥8,303.57 | +13.75% | 14 | |||||||
| GBX 16.66 | +14.96% | 19 | |||||||
| CN¥64.5 | +24.49% | 16 | |||||||
| ¥4,946.56 | +14.16% | 16 | |||||||
| GBX 4.246 | +10.5% | 17 | |||||||
| Average | 903.32 | +18.20% | 22 | ||||||
| Weighted average by Cap. | 612.14 | +19.03% | 23 |
- Stock Market
- Equities
- NOVO B Stock
- Sector Novo Nordisk A/S
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
